Radial basis function-generated finite difference scheme for simulating the brain cancer growth model under radiotherapy in various types of computational domains

Predicting the effect of a combination drug therapy on the prostate tumor growth via an improvement of a direct radial basis function partition of unity technique for a diffuse-interface model

Chemotherapy is usually applied to treat advanced prostate cancer that cancer cells spread outside the prostate gland. The treatment uses cytotoxic drugs to target cells that grow and divide quickly. On the other hand, the growth of such cancerous tumors depends on angiogenesis. In this paper, we numerically study a diffuse-interface model in a two-dimensional space related to the therapies of prostate cancer. The proposed model describes the tumor growth driven by a generic nutrient and producing the prostate-specific antigen. More precisely, the effect of cytotoxic chemotherapy in the model is evaluated by considering a time-dependent function in the tumor dynamics. Also, another function related to the antiangiogenic therapy is considered to show the reducing intratumoral nutrient supply in the nutrient dynamics. Here, a meshless approximation, i.e., a generalized form of the direct radial basis function partition of unity (D-RBF-PU) method is presented for finding the numerical simulations of this model utilizing in medical oncology. The method uses the lower number of trial points in each patch than the original D-RBF-PU scheme for approximating the trial function per test point. Hence, the time complexity of the method is less than the D-RBF-PU technique. Besides, a semi-implicit time discretization of order 1 has been used to deal with the time variable. Consequently, a linear system of algebraic equations could be solved iteratively per time step by the use of the biconjugate gradient stabilized method with zero-fill incomplete lower-upper preconditioner. Finally, the obtained results without using any adaptive algorithm demonstrate the response of the prostate tumor growth to the chemotherapy, antiangiogenic therapy and a combined therapy.